Publications

Journal Articles

  1. & Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy. European Endocrinology 13(01), 21
  2. & Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocrine Disorders 17(1)
  3. & Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion?. Diabetes & Metabolism
  4. & Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy. Diabetes, Obesity and Metabolism
  5. & A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. Diabetes, Obesity and Metabolism
  6. & Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. Current Medical Research and Opinion, 1-8.
  7. & Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Current Medical Research and Opinion, 1-11.
  8. & Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Current Medical Research and Opinion, 1-13.
  9. & Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Current Medical Research and Opinion, 1-13.
  10. & Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovascular Diabetology 16(1)
  11. & Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. Diabetes, Obesity and Metabolism 19(11), 1546-1554.
  12. & Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care, dc161769
  13. & Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973–981. Diabetes Care 39(10), e186-e187.
  14. & Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Therapy 7(2), 187-201.
  15. & Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. Reviews in Endocrine and Metabolic Disorders 17(1), 91-101.
  16. & Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β-Cell Function. The Journal of Clinical Endocrinology & Metabolism 101(2), 572-580.
  17. & Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. Primary Care Diabetes 10(1), 51-59.
  18. & When should screening for diabetic retinopathy begin for children with type 1 diabetes?. Expert Review of Endocrinology & Metabolism 11(2), 97-102.
  19. & Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. Journal of Diabetes and its Complications 30(8), 1622-1630.
  20. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opinion on Drug Metabolism & Toxicology 12(8), 977-987.
  21. & Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. Journal of Diabetes and its Complications 30(8), 1622-1630.
  22. & Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research and Clinical Practice
  23. & Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
  24. The dawn phenomenon in type 2 diabetes: How to assess it in clinical practice?. Diabetes & Metabolism 41(2), 132-137.
  25. & Incidence and progression of diabetic retinopathy within a private diabetes mellitus clinic in South Africa. Journal of Endocrinology, Metabolism and Diabetes of South Africa 20(3), 127-133.
  26. & “Mild dysglycemia” in type 2 diabetes: to be neglected or not?. Journal of Diabetes and its Complications 29(3), 451-458.
  27. & Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. Journal of Diabetes and its Complications 29(1), 134-141.
  28. & Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. British Journal of Ophthalmology 99(1), 64-68.
  29. & The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care. Drugs 74(8), 911-927.
  30. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes, Obesity and Metabolism 16(6), 560-568.
  31. & Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 16(7), 588-601.
  32. Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. Journal of Diabetes and its Complications 28(2), 191-195.
  33. & Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes. Diabetes Research and Clinical Practice 104(3), 370-375.
  34. & Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Diabetes Research and Clinical Practice 106(2), 264-274.
  35. & Basal insulin analogues in the management of diabetes mellitus: what progress have we made?. Diabetes/Metabolism Research and Reviews 30(2), 104-119.
  36. Guideline for management of postmeal glucose in diabetes. Diabetes Research and Clinical Practice 103(2), 256-268.
  37. & The Emergence of Biosimilar Insulin Preparations—A Cause for Concern?. Diabetes Technology Therapeutics 14(11), 989-996.
  38. & Response Letter to D. Singh-Franco et al.. Diabetes, Obesity and Metabolism 14(11), 1054-1055.
  39. Ethnic Differences in the Prevalence of Diabetic Retinopathy in Persons With Diabetes When First Presenting at a Diabetes Clinic in South Africa..
  40. Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. Diabetic Medicine, n/a-n/a.
  41. & Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, n/a-n/a.
  42. & Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice 66(8), 731-740.
  43. & Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. The Lancet 379(9833), 2262-2269.
  44. & Mobile diabetes eye care: Experience in developing countries. Diabetes Research and Clinical Practice 97(3), 343-349.
  45. & Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screening. Diabetic Medicine 29(7), 878-885.
  46. & Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experiment. Diabetic Medicine 29(7), 869-877.
  47. & Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 344(feb22 1), e874-e874.
  48. International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece..
  49. & Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1. Diabetic Medicine 28(11), 1352-1361.
  50. Insulin preparations with prolonged effect..
  51. Evaluation of an online interactive Diabetes Needs Assessment Tool (DNAT) versus online self-directed learning: a randomised controlled trial..
  52. & Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept' study. Diabetes, Obesity and Metabolism 13(11), 1020-1027.
  53. & Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes/Metabolism Research and Reviews 27(4), 348-353.
  54. & Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes, Obesity and Metabolism 13(3), 251-257.
  55. A longitudinal study into the new and long-term use of self-monitoring blood glucose strips in the UK..
  56. Daytime variability of postprandial glucose tolerance and pancreatic B-cell function using 12-h profiles in persons with Type 2 diabetes..
  57. Impending hyperglycemia in normoglycemic renal transplant recipients--an experimental predictive surrogate..
  58. Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients..
  59. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression..
  60. The pulse volume recorder as a measure of peripheral vascular status in people with diabetes mellitus..
  61. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes..
  62. Prevalence of diabetic macular oedema and related health and social care resource use in England..
  63. & Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53(3), 562-571.
  64. & Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53(3), 562-571.
  65. & Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 32(suppl_2), S260-S265.
  66. Complex interplay between insulinemia, glycemia, and glomerular filtration rate in nondiabetic renal transplant recipients..
  67. Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation..
  68. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.
  69. Use of cystatin C-based estimations of glomerular filtration rate in patients with type 2 diabetes..
  70. Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality..
  71. & Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 32(suppl_2), S260-S265.
  72. Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes..
  73. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application..
  74. Performance of the revised '175' Modification of Diet in Renal Disease equation in patients with type 2 diabetes..
  75. Simultaneous trend analysis for evaluating outcomes in patient-centred health monitoring services.
  76. Type 2 diabetes: a well-characterised but suboptimally controlled disease. Can we bridge the divide?.
  77. & Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet 371(9618), 1073-1084.
  78. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period..
  79. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?.
  80. Consensus report of the coalition for clinical research-self-monitoring of blood glucose..
  81. Influence of body weight on the performance of glomerular filtration rate estimators in subjects with type 2 diabetes..

Book Chapters

  1. & Short-Term Intensive Insulin Therapy in Persons with Newly Presenting Type 2 Diabetes Mellitus. In Endocrine and Metabolic Medical Emergencies: A Clinician's Guide. -278). Endocrine Press.